Lipoproteins in Diabetes Mellitus

Alicia Jenkins, MBBS, MD, FRACP, FRCPUniversity of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Oklahoma City, OK, USAPeter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACCCGH Medical Center, Sterling, ILUniversity of Illinois College of Medicine, Clinical Family and Community Medicine, Peoria, ILMichigan State University College of Osteopathic Medicine, Clinical Medicine, East Lansing, MI, USATimothy J. Lyons, MD, FRCP University of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Harold Hamm Diabetes Center, Oklahoma City, OK, USA

• Laboratory Assessment of Lipoproteins in Diabetes.- Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin Resistance Diabetes.-  Insulin Resistance and Atherosclerosis.-  Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes.- Lipoprotein Metabolism and Alterations induced by insulin resistance and diabetes.- Production and Metabolism of Triglyceride-Rich Lipoproteins in both the Normal and Diabetic States.- Lipoprotein(a): Structure, Metabolism and Pathophysiology.- Lipoprotein Glycation in Diabetes Mellitus.-Lipoprotein (LDL and  HDL) Oxidation in Diabetes Mellitus.- The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in Diabetes.- Lipid – Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes.- Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus.- Endothelial Dysfunction and Dyslipidaemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy.- Lipoproteins and Diabetic Nephropathy.- Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic Retinopathy.- Effects of Lifestyle (Diet, Plant Sterols, Excercise) and Glycemic Control on Lipoporteins in Diabetes.- About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus.- Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients.- The PPAR System in Diabetes.- Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients.- Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients.- Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus.- Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes.

From the book reviews: "This volume reviews in 23 chapters the lipid and lipoprotein changes induced by diabetes mellitus. It contains didactic color illustrations and many references. For clinical and research diabetologists, pharmacologists and biochemists." (Pediatric Endocrinology Reviews (PER), Vol. 12 (1), September, 2014)